On January 12, 2025, the rules governing company-level licensing of health product establishments in the Philippines were replaced outright. Administrative Order No. 2024-0015, issued by the Department of Health on November 27, 2024, repealed Administrative Order No. 2020-0017 and reset how licenses are applied for, how long they last, and what happens when a renewal is filed late. On the same date, a new schedule of fees took effect under Administrative Order No. 2024-0016. Any guidance written before 2025 describes a system that no longer applies.
The authorization at the center of it is the FDA license to operate. It is the company-level permit that allows an establishment to manufacture, import, export, distribute, wholesale, or sell products regulated by the Food and Drug Administration. Without it, an importer cannot clear customs, a manufacturer cannot lawfully produce, and no product registration can even be filed, because product authorizations are issued only to licensed establishments.
License validity is now tiered by enterprise size and can last up to 12 years. Fees are computed per year and multiplied by the validity chosen. The renewal window narrowed, widened, then narrowed again within a single year. Companies planning against the old two-year and five-year cycle are budgeting for a framework that was repealed.
What the License Actually Authorizes
The distinction that trips up most applicants is between the establishment and the product. They are licensed separately, the sequence is fixed, and an FDA license to operate sits at the front of it.
The FDA license to operate authorizes the company to engage in a regulated activity at all. Product authorizations, whether a Certificate of Product Registration, a Certificate of Product Notification for cosmetics, or a medical device notification or registration certificate, authorize individual items. The license comes first. There is no route to a product authorization for an unlicensed establishment.
The license is also activity-specific and category-specific. A food manufacturer, a cosmetics distributor, and a drug importer do not apply under the same license type, and an establishment performing more than one covered activity needs its license to reflect each of them. Administrative Order No. 2024-0015 also pulled in activities that were previously treated ambiguously, requiring a manufacturer’s license for three-dimensional printing of medical devices, optical establishments assembling lenses and frames, and dental laboratories producing custom-made dental devices.
The sales channel makes no difference. An online-only seller, a home-based operation, and a physical store all need the license. What the agency does require is a verifiable physical address, including storage facilities where products are distributed or imported. An applicant with no premises will not be approved.
Four Things That Determine the Outcome of an Application
- Enterprise Size Now Determines How Long the License Lasts
This is the single largest change, and it has direct financial consequences. Under Administrative Order No. 2024-0015, validity is tiered:
- Micro and small enterprises: initial license valid for 3 years, renewal valid for 6 years.
- Medium and large enterprises: initial license valid for 6 years, renewal valid for 12 years.
Enterprise size follows the standard Philippine classification by capital. A Department of Health circular applying the same order to pharmacies describes the brackets as micro and small enterprises with capital of not more than PHP 3 million and PHP 15 million, respectively, medium enterprises at not more than PHP 100 million, and large enterprises above PHP 100 million.
Two practical consequences follow. First, the classification recorded on the application drives a multi-year outcome, so it needs to be accurate rather than approximate. Second, because a renewal yields double the validity of an initial license, being pushed back into initial-application treatment is not a minor penalty. A medium enterprise that loses renewal status gives up six years of validity.
- Fees Are Annual, Multiplied by the Validity Granted
Administrative Order No. 2024-0016, which took effect on 12 January 2025 after publication in The Manila Times on 28 December 2024, restructured the fee schedule. The controlling rule is that fees for licenses and product authorizations are expressed as a yearly rate and multiplied by the allowable number of years of validity.
A worked illustration from the health department’s own guidance for pharmacies sets the license fee at PHP 3,000 annually, plus 1% for the Legal Research Fund, with the annual figure multiplied by the years of validity granted. The Legal Research Fee itself is PHP 10 or one percent of the application fee, whichever is higher.
Applications and surcharges submitted from 12 January 2025 are assessed under the new order; those lodged before that date remain under the old Administrative Order No. 50, series of 2001. Fees are subject to periodic review, so the order of payment generated by the system is the amount that governs.
Separately, there is an annual fee, defined by the agency as a yearly payment made by establishments to retain the validity of a license. Non-payment leads to revocation of the authorization. A multi-year license is not a multi-year holiday from payment obligations.
- The Renewal Window Is Narrow and Has Moved Twice
Under Administrative Order No. 2024-0015, a renewal application, whether automatic or regular, must be filed through the eServices Portal within 90 calendar days prior to the expiration of the license validity date. The system will not accept a filing well outside that window.
That rule was briefly relaxed. Advisory No. 2025-0095 announced that starting February 17, 2025, renewals would be accepted within 180 days before expiry instead of 90, as an interim measure while the agency worked through processing concerns, and confirmed that payment of the correct fee before expiry would not result in surcharges. Advisory No. 2025-0095-A then lifted that extension in July 2025, reverting the window to the prescribed 90 calendar days.
The lesson is not about the specific dates. It is that the filing window is an active regulatory variable, and the license itself, not a secondary source, is the authority on when a particular renewal opens.
- Late Filing Has a Cliff, Not a Slope
The penalty structure comes from the implementing rules of Republic Act No. 9711, the Food and Drug Administration Act of 2009, and it is stepped rather than proportional.
- A renewal received after the expiration date is subject to a surcharge equal to twice the renewal licensing fee, plus an additional ten percent of the renewal fee per month or fraction of a month of continuing non-submission, up to a maximum of 120 days.
- A renewal filed within 120 days of expiry keeps the license considered valid and existing until the agency renders a decision on the application, provided the applicable fees and surcharges are paid.
- A renewal filed beyond 120 days is considered expired. The application is charged the total surcharge plus the initial filing fee and must go through the initial application process, which also means reverting to the initial tier validity.
- A license due for renewal with no application filed is treated as expired and canceled after 120 days from the expiry date.
The cost of crossing day 121 is therefore not a late fee. It is the surcharge, plus initial application fees, plus the loss of half the validity the renewal would have granted.
What the Application Requires
Filing is exclusively electronic. Initial, renewal, and variation applications for covered establishments go through the FDA eServices Portal, and establishments are expected to maintain a single official email address for all official communication. Walk-in and manual filing are not options for covered categories.
A typical documentary package includes:
- The completed electronic application form with the required declaration and undertaking.
- Proof of business name registration from the Department of Trade and Industry, the Securities and Exchange Commission, or the Cooperative Development Authority.
- Proof of capitalization, generally the latest audited financial statements or a duly notarized certification of initial capitalization, for manufacturers and traders.
- Proof of occupancy or ownership of the premises, with a location plan and Global Positioning System coordinates.
- The name and Professional Regulation Commission credentials of the Qualified Person in charge. Drug establishments require a licensed pharmacist; other categories require appropriate technical personnel.
- A Risk Management Plan, and for manufacturers, a Site Master File and floor plan, to be presented during inspection.
- Contracts of agreement where outsourcing or contract manufacturing is involved.
- Payment of the pre-assessment fee, where applicable, and of the license fee upon issuance of the order of payment.
The agency retains inspection authority throughout, including pre-licensing inspections, routine inspections, and other inspections it deems necessary, conducted on-site or in hybrid form, with inspectors able to take copies of relevant documents.
When to Start the Process
- Before Incorporating the Import Plan: Customs will not release a shipment of regulated products without a valid license from the importer. Licensing belongs in the pre-shipment critical path, not after arrival.
- Before Any Product Filing: Product registration cannot be lodged without an active FDA license to operate, so licensing timelines govern launch timelines.
- At Least Six Months Before Expiry: The filing window opens 90 days out, but third-party documents such as permits, leases, and authorization letters take longer to reassemble than most teams expect.
- When Adding an Activity: Moving from distribution into repacking, or from wholesale into importation, changes the license type and requires a variation rather than a quiet operational shift.
- When the Qualified Person Leaves: The appointment is a licensing condition, not an internal HR matter.
- When Enterprise Size Changes Materially: Capital growth can move an establishment between validity tiers at the next filing.
- When a Deficiency Letter Arrives: Deficiency responses carry their own deadlines, and missing one restarts work that has already been paid for.
What Good Licensing Management Delivers
- Longer Intervals Between Filings: A medium or large enterprise that renews on time can hold a license for twelve years, replacing a recurring administrative burden with a single well-executed filing.
- Predictable Cost: Because fees are annualized and multiplied by validity, the total license cost is calculable at the planning stage.
- Uninterrupted Trading: Filing within the window and paying the correct fee before expiry keeps the license in force and avoids the gap that stops shipments and delistings.
- Clean Product Pipeline: A current FDA license to operate is the precondition for every product authorization the company will ever file.
- Verifiable Standing: Licensed establishments and approved authorizations can be checked in the agency’s public verification records, which distributors, marketplaces, and institutional buyers increasingly do before onboarding.
- A Route to Challenge a Decision: Administrative Order No. 2024-0015 institutionalized an administrative reconsideration mechanism in the licensing process, giving applicants a defined path rather than an informal appeal.
A Process That Rewards Complete Filings
An application for an FDA license to operate is a highly technical transaction, and Republic Act No. 11032, the Ease of Doing Business and Efficient Government Service Delivery Act of 2018, caps the prescribed processing period for highly technical transactions at twenty working days, extendable once, with the count starting only from receipt of a complete application. Completeness, not follow-up, is what moves a file.
The consequences of operating without a license sit at the other end of the scale. Section 11 of Republic Act No. 9711 makes the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, or advertising of unregistered or otherwise non-compliant health products a prohibited act, carrying imprisonment of one to ten years and a fine of PHP 50,000 to PHP 500,000, alongside administrative fines, continuing daily penalties, and suspension or cancellation of authorizations.
Final Insights
The FDA license to operate is the company-level authorization that precedes every product filing, every lawful import, and every compliant sale of a regulated health product in the Philippines. Since January 12, 2025, it has been governed by Administrative Order No. 2024-0015, which tiers validity by enterprise size at three years initial and six on renewal for micro and small enterprises, and six years initial and 12 on renewal for medium and large ones, with all applications filed through the eServices Portal.
The economics now turn on timing. Fees are charged per year and multiplied by the validity granted. An annual fee must be paid to keep the license alive, and the renewal window is 90 calendar days before expiry. File within it, and the license runs for its full renewed term. File after expiry, and the surcharge is twice the renewal fee plus ten percent per month. If the file is more than 120 days late, the license is treated as expired, the application reverts to the initial filing, and half the potential validity is gone. Licensing in this framework is a calendar discipline first and a documentation exercise second.
Is Assistance Available?
Yes, Business Registration Philippines delivers complete, end-to-end registration and compliance management as a trusted specialist, ensuring your corporation is legally operational in weeks, not months, after filing. Our proven expertise turns regulatory complexity into an immediate competitive advantage. Reach out today to schedule an initial consultation with one of our experts:
- Contact Us Here
- Fill Out the Form Below
- Call us at +63 (02) 8540-9623